ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO834

The Effect of Combined Therapy with Peritoneal Dialysis and Hemodialysis on Patient Survival: A Prospective Multicenter Study in Japan

Session Information

  • Peritoneal Dialysis - I
    November 02, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

  • 608 Peritoneal Dialysis

Authors

  • Maruyama, Yukio, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Yokoyama, Keitaro, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Nakayama, Masaaki, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Higuchi, Chieko, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Sanaka, Tsutomu, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Tanaka, Yoshihide, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Sakai, Ken, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Kanno, Yoshihiko, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Ryuzaki, Munekazu, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Sakurada, Tsutomu, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan
  • Hosoya, Tatsuo, EARTH (Evaluation on the Adequacy of Renal Replacement Therapy) Study Group, Tokyo, Japan

Group or Team Name

  • EARTH Study Group
Background

Combined therapy with peritoneal dialysis (PD) and hemodialysis (HD) was widely performed to correct underdialysis and/or overhydration in Japan. However, its clinical result was only reported in retrospective observational studies, and the effect on patient survival is unknown. Hence, we conducted a prospective study to investigate its clinical efficacy in Japan.

Methods

In this prospective multicenter study, we recruited 164 patients started PD from January 1, 2011 to December 31, 2016 (59±16 years, 118 males, and 61 diabetes), and collected clinical information on an annual basis until March 31, 2017.

Results

Median follow-up period was 35 months (range, 0-71 months). During follow-up, 21 patients were switched to the combined therapy with PD and HD, and 15 were switched to HD alone 30±16 and 23±13 months after PD initiation, respectively. The reasons for switching therapy were underdialysis in 8 (22%), overhydration in 12 (33%), both in 1 (3%), and others or unknown in 15 patients (42%). Nineteen patients (11.6%) died of all causes, including 6 (3.7%) died of CVD. Sixteen patients on PD alone, 1 patient on HD alone, and 2 patients on combined therapy were dead. Mortality after switching therapy was no significantly difference between patients on HD alone and those on combined therapy (Log-rank p=0.25, Figure 1).

Conclusion

The effect of switching combined therapy with PD and HD from PD alone on patient survival could not be inferior to switching HD directly. Long-term observation is needed to prove survival advantage of combined therapy.

Funding

  • Commercial Support